Lundbeck receives approval from Health Canada for Treanda® (bendamustine hydrochloride for injection) to treat patients with relapsed indolent B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia
· Canadians diagnosed with two common types of cancer now have a new treatment option available to them · Treanda has been approved since 2010 in Europe and 2008 in the US in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin’s lymphoma (iNHL) that has progressed · Treanda is a new treatment option that offers a delay in disease progression · It is estimated that there are approximately 2,500 patients diagnosed with iNHL and 1,400 diagnosed with CLL in Canada every year · Canada is one of Lundbeck’s most important markets and the addition of